hVIVO Company Description

hVIVO plc operates as a full-service early specialist contract research organisation in the United Kingdom, Europe, and North America.

It provides end-to-end early clinical development services to the biopharmaceutical industry, including phase I capabilities and world leading human challenge trial services.

The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including virology, immunology and biomarker analysis, as well as assay development, sample analysis, and data interpretation.

In addition, the company offers services combined with specialisms in infectious diseases, respiratory, and cardiometabolic therapeutical areas.

Further, it provides preclinical and early clinical research services; sales and marketing services; data management; storage solutions; and statistics services, as well as drug development consultancy and services.

The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.

hVIVO plc

Country	United Kingdom
Industry	Biotechnology
Sector	Healthcare
Employees	376
CEO	Yamin Khan

Contact Details

Address: 40 Bank Street London, E14 5NR United Kingdom
Phone	44 20 7756 1300
Website	hvivo.com

Stock Details

Ticker Symbol	HVO
Exchange	London Stock Exchange AIM
Fiscal Year	January - December
Reporting Currency	GBP
ISIN Number	GB00B9275X97
SIC Code	8731

Key Executives

Name	Position
Yamin Khan	Chief Executive Officer
Stephen Pinkerton	Chief Financial Officer